Alvaro Amorrortu is an experienced leader with deep background in large-scale transformations and infrastructure build-outs. His experience is drawn from his work across different functions; from manufacturing and process development to marketing and human resources.

Currently, he is the CEO of Mediphage Bioceuticals, a Toronto based start-up that is developing a novel non-viral gene therapy platform, leveraging its ministringDNA (msDNA) technology. Prior to Mediphage, Alvaro was the COO of Solid Biosciences, where he was responsible for building the infrastructure to execute Solid’s clinical trial (gene therapy for Duchenne Muscular Dystrophy patients). Prior to joining Solid Biosciences, he spent more than a decade as a management consultant advising biopharmaceutical and other companies on a variety of strategic challenges. His career as a strategist started at the Monitor Group, and then a few years at Syneos Health before moving to the biotech world. In addition, Alvaro has hands on experience managing operations. He held leadership positions in Bunge Group and Cargill subsidiaries, where he was responsible for designing and running complex engineering projects in manufacturing facilities.

At Dunster, Alvaro would love to share with students his experience living in different parts of the world, leading teams from very diverse cultural backgrounds and working in large corporations as well as in start ups. Mr. Amorrortu received his M.B.A. with a major in Finance from The Wharton School and graduated from the Instituto Tecnologico de Buenos Aires, Argentina with an MS in Industrial Engineering. An avid traveler, he has lived and worked in Argentina, Paraguay, Spain, Switzerland and the United States. He is married to Virginia, and they have three children, Candela, Francisco and Pedro.